INSIGHTS ON ENTERPRISE SOLUTIONS
-
![From The Floor at cphi 2025]( "From The Floor At CPHI 2025: Takeaways Everyone Should Know")
From The Floor At CPHI 2025: Takeaways Everyone Should KnowGain insights into evolving pharma priorities, from supply chain resilience to advanced manufacturing, and why flexibility, scalability, and technical expertise matter in a dynamic global market.
-
![Bora Pharmaceuticals CDMO capabilities overview]( "CDMO Capabilities Overview")
CDMO Capabilities OverviewExplore global CDMO capabilities that streamline drug development and manufacturing, leveraging advanced infrastructure and regulatory expertise from early formulation through commercial production.
-
![Bora Pharmaceuticals - Zhunan Facility Site VR Tour]( "Zhunan Facility Site VR Tour")
Zhunan Facility Site VR TourBora’s 36,000-square-meter Zhunan, Taiwan facility delivers flexible, high-quality cGMP oral solid dose manufacturing with access to major markets including North America and the EU.
-
![Bora Corporate Overview 2025]( "Corporate Overview 2025: Business Strategy & Outlook")
Corporate Overview 2025: Business Strategy & OutlookExplore how a growing pharma organization uses innovation, regulatory expertise, and strategic partnerships to deliver targeted therapies and drive impact across the evolving healthcare landscape.
-
State-Of-The-Art CDMO Facility - Maple Grove12/22/2025
Discover how a U.S.-based CDMO combines advanced infrastructure, quality-driven processes, and flexible manufacturing to support pharmaceutical development and commercial supply.
-
The Impact Of PEGs In The Small Molecule API Market12/22/2025
Explore how PEG selection shapes drug development success by understanding the benefits of expert CDMO partnerships that deliver custom solutions to enhance your small molecule program.
-
Periodic Counter Current Chromatography: A Step Toward Continuous DSP12/19/2025
PCC boosts Protein A capture efficiency, cuts resin costs, increases productivity, and enables continuous downstream processing without sacrificing quality or compliance.
-
Agile Adaptation In mRNA-LNP Manufacturing: A CDMO's Response12/17/2025
Find flexible scale-up from lab through commercial manufacturing, leveraging expertise. Gain technical insights for scalable, efficient development for advancing mRNA, saRNA, or circular RNA programs.
ENTERPRISE SOLUTIONS
-
![GettyImages-506999858-scientists-cell-culture-lab-development]( "Viral Clearance Testing For Biologics, Vaccines & AAV Therapies")
Viral clearance protects patients by validating virus removal and inactivation in biologics manufacturing, meeting global standards through rigorous, audit-ready studies and expert oversight.
-
![Asahi Kasei - VANTIJ]( "VANTIJ® Single-Use Virus Filtration Controller")
Automating critical filtration steps significantly reduces cross-contamination risks and operational costs. This single-use approach ensures process repeatability and eliminates cleaning downtime.
-
![GettyImages-1351826681-capping-vials-fill-finish]( "Aseptic Manufacturing: Fill/Finish For Vials, Syringes, Cartridges")
Sterile fill/finish requires isolator technology and regulatory compliance. From clinical development to commercial scale, technical expertise ensures the integrity of liquid and lyophilized injectables.
-
![GettyImages-2154728338 global]( "Minaris Advanced Therapies Overview")
Global cell and gene therapy CDMO providing GMP manufacturing, testing, and development services with commercial success, regulatory expertise, and advanced multi‑modality capabilities.
-
![GettyImages-1331874048 MSC, stem cells]( "Cell Therapy Lot Release Package")
Comprehensive cGMP-compliant cell therapy lot release testing includes identity, potency, safety, and characterization assays, ensuring regulatory compliance and timely product release for advanced therapies.
